Trial Profile

A Prospective Registry of Patients With a Confirmed Diagnosis of Adenocarcinoma of the Prostate Presenting With Metastatic Castrate-Resistant Prostate Cancer

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 16 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abiraterone acetate (Primary) ; Docetaxel (Primary) ; Enzalutamide (Primary) ; Prednisolone (Primary) ; Prednisone (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Therapeutic Use
Acronyms The Prostate Cancer Registry (PCR)

Most Recent Events

01 Nov 2022 Results (n=3003; from June 14, 2013 to July 9, 2018) assessing to increase the understanding of real-world treatment pathways and outcomes in patients with metastatic castration-resistant prostate cancer, published in the European Urology Open Science.
09 Apr 2022 Results (n= 238) from Italian cohort of the Prostate Cancer Registry published in the Tumori
07 Apr 2021 Results (n=3003) published in the Targeted Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com